Physician profile
Donald E Winder
NPI 1336411636
$1,263.12
in general payments reported to CMS, 2019-2025
18 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.33 · 2022: $282 · 2023: $624 · 2024: $180 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $363.80 | 2022-2024 | Proclaim, Eterna |
| Averitas Pharma INC. | $258.71 | 2023 | Qutenza |
| Abbvie INC. | $172.88 | 2022-2024 | |
| Pfizer INC. | $138.29 | 2023-2025 | |
| Amgen INC. | $36.20 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $29.91 | 2024-2025 | Trelegy Ellipta |
| Merz Pharmaceuticals, LLC | $28.99 | 2023 | Xeomin |
| Grt US Holding, INC. | $25.14 | 2022 | |
| Daiichi Sankyo INC. | $24.68 | 2024 | Injectafer |
| Collegium Pharmaceutical, INC. | $23.32 | 2024 | Belbuca |
| Sanofi-Aventis U.S. LLC | $23.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.90 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.37 | 2022 | |
| Corcept Therapeutics | $21.43 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $21.33 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $20.46 | 2024 | Horizant |
| Xeris Pharmaceuticals, INC. | $14.82 | 2025 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $14.79 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Winder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.